All In Biotech

Drug Trial Radar · NCT05664217

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

A Phase 2/3, Randomized, Double Blind, Placebo-controlled, Multicenter Study of NKTR-255 vs Placebo Following CD19-directed CAR-T Cell Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

15

Actual

Start

Feb 23, 2023

Primary completion

May 22, 2024

Study completion Aug 16, 2024

Sponsor

Lead sponsor
Nektar TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Nektar Study 18-255-01 was a Phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 versus placebo following CD19-directed CAR-T cell therapy in patients with R/R LBCL. This study was to be run in 2 parts: Phase 2 (Stage 1) and Phase 3 (Stage 2). This study evaluated the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 was an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Chimeric antigen (CAR)-T cell product consists of genetically engineered T-cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 following the treatment with CD19 CAR-T cell therapy may work better in treating large B-cell lymphoma than either drug alone.

Conditions

  • Non-Hodgkin Lymphoma
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventions

  • NKTR-255 at 1.5 µg/kgDrug

    NKTR-255 at 1.5 µg/kg

  • NKTR-255 at 3.0 μg/kgDrug

    NKTR-255 at 3.0 μg/kg

  • NKTR-255 at 3.0/6.0 μg/kgDrug

    NKTR-255 at 3.0/6.0 μg/kg

  • Placebo ComparatorOther

    Commercially available 0.9% Sodium Chloride Solution for Injection (USP)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response (CR) RateTime frame: At month 6

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Kansas Cancer Center

    Fairway, Kansas

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • NYU Langone Medical Center

    New York, New York

  • Novant Health Cancer Institute

    Charlotte, North Carolina

  • Oncology Hematology Care Inc - Cincinnati

    Cincinnati, Ohio

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.